FDA panel on peptides

The Food and Drug Administration will ask outside advisers in July whether compounding pharmacies should be allowed to make seven peptide ingredients again. (fda.gov) The agency scheduled a two-day meeting of its Pharmacy Compounding Advisory Committee for July 23 and July 24, 2026, after publishing a notice in the Federal Register on April 16. (federalregister.gov) Peptides are short chains of amino acids, the chemical pieces that also make up proteins, and many of the products at issue are sold with claims about wound healing, inflammation, obesity, sleep, or “longevity.” (reuters.com) (fda.gov) The seven substances on the July agenda are BPC-157, KPV, TB-500, MOTs-C, emideltide, semax, and epitalon, each listed in both free-base and acetate forms. The Food and Drug Administration says the panel will discuss whether they belong on the Section 503A bulks list, which governs what traditional compounding pharmacies can use to mix patient-specific drugs. (fda.gov) (ecfr.gov) This is not the same as Food and Drug Administration approval. The question is whether pharmacies can compound these ingredients under a prescription, not whether the agency has found them safe and effective for general marketing. (fda.gov) (ecfr.gov) The review reopens a fight the agency seemed to settle in 2023, when it removed 19 peptides from the list of bulk substances that compounders were allowed to use. Stat News reported the July panel will consider adding back seven of those peptides, with five more to be discussed at a later meeting. (statnews.com) (reuters.com) The policy shift follows months of public pressure from Health and Human Services Secretary Robert F. Kennedy Jr., who has praised peptides in interviews and said federal regulators should widen access. ABC News and the Associated Press reported the products have become popular with wellness influencers, fitness figures, and celebrities. (abcnews.com) (politico.com) Supporters say doctors and pharmacists should have more room to prepare customized treatments for individual patients. Critics say many of these injections are backed by thin evidence and can reach consumers through anti-aging and “biohacking” clinics faster than the science develops. (reuters.com) (nbcnews.com) Public Citizen, a consumer advocacy group, said the July meeting would test whether the agency follows scientific evidence or political pressure. The group said the seven peptides were removed three years ago because of safety and effectiveness concerns. (citizen.org) The committee will vote on advice, not make the final call itself, and the Food and Drug Administration is accepting public comments in docket FDA-2025-N-6895 before the meeting. The next concrete date in this fight is July 23. (federalregister.gov)